MPN Cancer Connection

Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting

Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data from the Phase 1 AJX-101 study showing that its investigational type II JAK2...

First global approval of BESREMi® in essential thrombocythemia supports continued expansion of the PharmaEssentia MPN franchise; 👇

U.S. PDUFA date remains on track for August 30, 2026

https://www.businesswire.com/news/home/20260610421769/en/PharmaEssentia-Announces-Taiwan-Approval-of-BESREMi-for-Essential-Thrombocythemia-Marking-First-Global-Approval-in-ET

TP53 Mutation Acquisition Timing Influences Prognosis in Myeloproliferative Neoplasms

Timing of TP53 Mutation Acquisition Influences Prognosis in Myeloproliferative Neoplasms Findings may help guide discussions around prognosis and allogeneic stem cell transplantation

Ropeginterferon alfa-2b for prefibrotic myelofibrosis and lower-risk myelofibrosis requiring cytoreduction

Ropeginterferon alfa-2b for prefibrotic myelofibrosis and lower-risk myelofibrosis requiring cytoreduction Key PointsRopeg showed clinically relevant activities and manageable safety in patients with early MF.After 104 weeks, ropeg resulted in reductions in VAF

PharmaEssentia taps Incyte alum Eric Vogel as it eyes Besremi expansion

PharmaEssentia taps Incyte alum Eric Vogel as it eyes Besremi expansion PharmaEssentia has hired Eric Vogel as its new U.S. Head of Commercialization, as it seeks to broaden the label of its rare blood cancer drug, Besremi, to a much wider market. | PharmaEssentia has hired Eric Vogel as its new U.S. Head of Commercialization as it seeks to broaden the label of its rare...

Seven years. Two medications. Five failed doctors.

When I was diagnosed with polycythemia vera in 2009, no one told me remission was possible. The only treatment I was offered, phlebotomy, guaranteed it wouldn't be.

Today my blood counts are normal. The molecular markers driving my PV are undetectable.

I just published the most personal article I've ever written. It covers how I got here, what it cost, the moment at ASH 2015 that changed everything, and what I want every PV patient to know.

This isn't a typical outcome. I won't pretend it is. But most patients are never told deeper responses are even on the table, and they deserve to know.

📖 Read the full story: https://pvreporter.com/polycythemia-vera-molecular-remission/

MDM2 inhibitors in myeloid cancers: from basic biology to clinical use in myeloproliferative neoplasms

MDM2 inhibitors in myeloid cancers: from basic biology to clinical use in myeloproliferative neoplasms - Leukemia Pharmacologic targeting of murine double minute 2 (MDM2) represents one of the most compelling strategies for therapeutic reactivation of wild-type p53 in hematologic malignancies. The MDM2–p53 autoregulatory loop is a central regulator of cellular stress responses, and in myeloid neoplasms—incl...

🚨 BREAKING NEWS: The FDA just approved Jakafi XR

A once-daily tablet of ruxolitinib for MF, PV and GVHD patients. Same proven medication, one pill a day. Available at pharmacies as early as May 8. This is big news for our community.

---> Talk with your MPN specialists folks, this will be news to many and more information will be forthcoming.

Read the full story:

One Pill, Once A Day: FDA Approves Jakafi XR | PV Reporter The FDA just approved Jakafi XR, a once-daily ruxolitinib tablet for MF, PV and GVHD patients. Same proven treatment, simpler daily routine.

We lost a great one this week.

Dr. Richard T. Silver passed away on April 17, 2026. He was 97 years old, and he used every one of those years.

For PV and MPN patients, his contributions are everywhere, in the treatments we take, the doctors who care for us, and the research that gives us hope. Some of us just didn't know his name. That changes today.

He helped shape modern hematology. He mentored the specialists treating us right now. He built a cancer research charity from scratch that has funded $17 million in grants. He journeyed into the Amazon. He played the clarinet on weekends.

And through all of it, patients came first.

I was fortunate enough to meet him in 2023. I wrote this piece because our community deserves to know who he was and how much we owe him.

Rest in peace, Dr. Silver. 🙏

Remembering Dr. Richard T. Silver (1929–2026): MPN Pioneer | PV Reporter Dr. Richard T. Silver, the Weill Cornell hematologist who introduced interferon for MPNs and helped launch imatinib for CML, has died at 97. A tribute.

🔬 New Hope in the Fight Against Aggressive Blood Cancers

​A recent study published in Bone Marrow Transplantation provides a vital update on treating blast-phase myeloproliferative neoplasms (MPN-BP). While this condition is traditionally highly aggressive, new data shows that allogeneic stem cell transplantation is offering a curative path for approximately one-third of patients.

https://www.nature.com/articles/s41409-026-02842-z